Anthracycline-Antibody Conjugates for Cancer Therapy
AssigneeImmunomedics, Inc.
InventorsGary L. Griffiths, Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.
Claims41
A method of treating cancer in a subject comprising administering to the subject a pharmaceutical composition comprising a conjugate of an anthracycline drug and an anti-CD74 antibody or antigen-binding fragment thereof.
A pharmaceutical composition for the treatment of cancer comprising a conjugate of an anthracycline drug and an anti-CD74 antibody or antigen-binding fragment thereof, wherein said anthracycline drug and said antibody or antibody fragment are linked via a linker comprising a hydrazide and a maleimide.
Dependencies are inferred from the claim text.